Disclosures for "Delayed Onset Cryptogenic Organizing Pneumonia in Alemtuzumab Treatment Patient")
-
Dr. Cheng has nothing to disclose.
-
Dr. Lannen has received personal compensation in the range of $5,000-$9,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Genentech. Dr. Lannen has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for TG Therapeutics.